E
Alector, Inc. ALEC
$1.04 -$0.05-4.59%
Recommendation
Sell
Prev Close
$1.09
Volume
460,135
Avg Vol (90D)
1,091,069
Market Cap
$108.00M
Dividend & Yield
--
52-Week Range
$1.09 - $6.78
P/E (TTM)
--
EPS (TTM)
-$1.24
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages
4/1/2025 - MarketBeat
Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Analysts
3/31/2025 - Ticker Report
Alector (NASDAQ:ALEC) Shares Down 3% - Here's Why
3/30/2025 - MarketBeat
Alector Provides Executive Leadership Update
3/28/2025 - GuruFocus
Alector Announces Resignation of Chief Medical Officer
3/28/2025 - TipRanks Financial Blog
Alector Provides Executive Leadership Update
3/28/2025 - Globe Newswire
Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%
3/21/2025 - Simply Wall St
Commit To Purchase Alector At $1, Earn 17.2% Annualized Using Options
3/19/2025 - Stock Options Channel
Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point
3/13/2025 - SeekingAlpha
Have Alector Insiders Been Selling Stock?
3/10/2025 - Simply Wall St
Morgan Stanley Reaffirms Underweight Rating for Alector (NASDAQ:ALEC)
3/8/2025 - MarketBeat
Alector assumed with an Underweight at Morgan Stanley
3/7/2025 - The Fly
FY2025 EPS Estimates for Alector Raised by Cantor Fitzgerald
3/3/2025 - MarketBeat
HC Wainwright Has Positive Estimate for Alector Q1 Earnings
3/3/2025 - MarketBeat
William Blair Has Pessimistic Outlook of Alector Q1 Earnings
3/3/2025 - MarketBeat
FY2029 Earnings Forecast for Alector Issued By HC Wainwright
3/1/2025 - MarketBeat
What is William Blair's Forecast for Alector Q1 Earnings?
3/1/2025 - MarketBeat
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts
3/1/2025 - Simply Wall St
Alector (NASDAQ:ALEC) Receives "Buy" Rating from HC Wainwright
2/28/2025 - MarketBeat
Alector (NASDAQ:ALEC) Issues Quarterly Earnings Results, Beats Estimates By $0.59 EPS
2/28/2025 - MarketBeat
Alector (ALEC) Receives a Sell from Bank of America Securities
2/27/2025 - TipRanks Financial Blog
HC Wainwright Reaffirms Buy Rating for Alector (NASDAQ:ALEC)
2/27/2025 - Ticker Report
Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...
2/27/2025 - GuruFocus
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
2/27/2025 - Seeking Alpha: Transcripts
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
2/27/2025 - SeekingAlpha
Income Statement
Total Revenue (TTM)
$100.56M
EBITDA (TTM)
-$137.39M
EBIT (TTM)
-$142.79M
Net Income (TTM)
-$119.05M
Balance Sheet
Total Assets (Q)
$468.30M
Total Debt (Q)
$42.52M
Total Liabilities (Q)
$341.50M
Book Value Per Share (Q)
$1.28
Cash Flow
Cash from Operations (TTM)
-$229.91M
Cash from Investing (TTM)
$107.13M
Cash from Financing (TTM)
$81.54M
Net Change in Cash (TTM)
-$41.23M
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.26
7-Day Total Return
-20.00%
30-Day Total Return
-44.39%
60-Day Total Return
-47.47%
90-Day Total Return
-72.34%
Year to Date Total Return
-44.97%
1-Year Total Return
-81.94%
2-Year Total Return
-82.72%
3-Year Total Return
-92.70%
5-Year Total Return
-95.56%
52-week Low
Apr 03, 2025 - $1.09
52-week High
Jul 23, 2024 - $6.78
Valuation
Market Cap
$108.00M - Micro Cap
Enterprise Value
-$262.87M
Price/Sales (TTM)
1.07
Price/Book (Q)
0.85
Dividends and Shares
Shares Outstanding
98.32M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alector.com
Phone Number
415 231 5660
Address
131 Oyster Point Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company’s products... more
NASDAQ 04/04/2025 12:37PM Eastern Quotes delayed
Weiss Ratings